lobbying_activities: 2870180

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2870180	f4bc27cb-ed05-458d-82b9-b05fc8a8e4b2	Q3	PUBLIC CITIZEN	32362	PUBLIC CITIZEN	2022	third_quarter	PHA	Drug price patent licensing executive action, INSULIN act, Licensing Government owned COVID technologies, Exercising executive licensing authorities to lower drug prices, HR 7900-NDAA amendment on Public protection of insulin for DOD, reconciliation drug price reform, and drug price negotiation provisions, Executive action to expand monkey pox Vaccine access, Global Covid 19 funding, HR 5376-Inflation reduction Act-drug pricing reform, insulin and drug price negotiation provisions, global and domestic monkey pox funding, Prescription Drugs affordability and access act, We PAID Act, USG support for mRNA hub	HOUSE OF REPRESENTATIVES,SENATE,White House Office		70000	0	0	2022-10-18T10:10:22-04:00